stocknshares
Minnesota-based gene editing technology developer, BlueAllele, has recently taken a legal swipe at Intellia Therapeutics (NASDAQ:NTLA) by lodging a patent infringement lawsuit in a Delaware federal court. In this David versus Goliath battle, BlueAllele contends that Intellia has trespassed on three of its patents relating to bio-directional insertion template technology.
BlueAllele, in bold defiance, pointed out that Intellia has surreptitiously utilized its proprietary platform technology to propel both internal initiatives and collaborative ventures.
In a dramatic twist, the legal tangle has even entwined Regeneron (REGN), where Intellia’s $100 million partnership seems to have opened a Pandora’s box. Faced with this legal onslaught, Intellia, depicted as silent as a church mouse, has refrained from offering any immediate rebuttal.
The charm offensive between Intellia and Regeneron, which extended their partnership arm in October, aiming at CRISPR-based therapies for neurological and muscular afflictions, now appears to be at the mercy of legal crossfire. The duo has also been laboring over treatments for conditions like ATTR and hemophilia, a saga rich in irony, given their present predicament.